Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity

Journal of Immunology

Volumn 193, Issue 3, 2014, Pages 1324-1332

  Pérez Girón, José V ^a   Belicha Villanueva, Alan ^b   Hassan, Ebrahim ^a   Gómez Medina, Sergio ^a   Cruz, Jazmina L G ^a   Ludtke, Anja ^a   Ruibal, Paula ^a   Albrecht, Randy A ^b   García Sastre, Adolfo ^b   Muñoz Fontela, César ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSE SEQUENCE; DRUG MECHANISM; DRUG POTENTIATION; HEMATOPOIETIC CELL; IMMUNOSTIMULATION; INFLUENZA A (H1N1); INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIORESISTANT NONHEMATOPOIETIC CELL; SIGNAL TRANSDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HEK293 CELLS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NASAL MUCOSA; POLY I-C; UP-REGULATION; VACCINES, ATTENUATED; VIRUS REPLICATION;

EID: 84906089277     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400222     Document Type: Article

References (45)

1. Medina, R. A., and A. García-Sastre. 2011. Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9: 590-603.
2. Thomas, P. G., S. A. Brown, R. Keating, W. Yue, M. Y. Morris, J. So, R. J. Webby, and P. C. Doherty. 2007. Hidden epitopes emerge in secondary influenza virus-specific CD8+ T cell responses. J. Immunol. 178: 3091-3098.
3. Epstein, S. L., W. P. Kong, J. A. Misplon, C. Y. Lo, T. M. Tumpey, L. Xu, and G. J. Nabel. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
4. Slütter, B., L. L. Pewe, S. M. Kaech, and J. T. Harty. 2013. Lung airwaysurveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity 39: 939-948.
5. Nabel, G. J., and A. S. Fauci. 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16: 1389-1391.
6. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
7. GeurtsvanKessel, C. H., M. A. Willart, L. S. van Rijt, F. Muskens, M. Kool, C. Baas, K. Thielemans, C. Bennett, B. E. Clausen, H. C. Hoogsteden, et al. 2008. Clearance of influenza virus from the lung depends on migratory langerin+CD11b2 but not plasmacytoid dendritic cells. J. Exp. Med. 205: 1621-1634.
8. Helft, J., B. Manicassamy, P. Guermonprez, D. Hashimoto, A. Silvin, J. Agudo, B. D. Brown, M. Schmolke, J. C. Miller, M. Leboeuf, et al. 2012. Crosspresenting CD103+ dendritic cells are protected from influenza virus infection. J. Clin. Invest. 122: 4037-4047.
9. Pepper, M., and M. K. Jenkins. 2011. Origins of CD4(+) effector and central memory T cells. Nat. Immunol. 12: 467-471.
10. Woodland, D. L., and J. E. Kohlmeier. 2009. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat. Rev. Immunol. 9: 153-161.
11. Medzhitov, R. 2007. Recognition of microorganisms and activation of the immune response. Nature 449: 819-826.
12. Ichinohe, T., I. Watanabe, S. Ito, H. Fujii, M. Moriyama, S. Tamura, H. Takahashi, H. Sawa, J. Chiba, T. Kurata, et al. 2005. Synthetic doublestranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J. Virol. 79: 2910-2919.
13. Pleschka, S., R. Jaskunas, O. G. Engelhardt, T. Zürcher, P. Palese, and A. García-Sastre. 1996. A plasmid-based reverse genetics system for influenza A virus. J. Virol. 70: 4188-4192.
14. Muñoz-Fontela, C., M. Pazos, I. Delgado, W. Murk, S. K. Mungamuri, S. W. Lee, A. García-Sastre, T. M. Moran, and S. A. Aaronson. 2011. p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. J. Immunol. 187: 6428-6436.
15. Cox, R. J., K. A. Brokstad, and P. Ogra. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59: 1-15.
16. Chan, W., H. Zhou, G. Kemble, and H. Jin. 2008. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 380: 304-311.
17. Falcón, A. M., A. Fernandez-Sesma, Y. Nakaya, T. M. Moran, J. Ortín, and A. García-Sastre. 2005. Attenuation and immunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteins. J. Gen. Virol. 86: 2817-2821.
18. García-Sastre, A., and C. A. Biron. 2006. Type 1 interferons and the virus-host relationship: a lesson in détente. Science 312: 879-882.
19. Ballesteros-Tato, A., B. León, F. E. Lund, and T. D. Randall. 2010. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. Nat. Immunol. 11: 216-224.
20. Kasturi, S. P., I. Skountzou, R. A. Albrecht, D. Koutsonanos, T. Hua, H. I. Nakaya, R. Ravindran, S. Stewart, M. Alam, M. Kwissa, et al. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
21. Grebe, K. M., J. W. Yewdell, and J. R. Bennink. 2008. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10: 1024-1029.
22. Bodewes, R., J. H. Kreijtz, C. Baas, M. M. Geelhoed-Mieras, G. de Mutsert, G. van Amerongen, J. M. van den Brand, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2009. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE 4: e5538.
23. Sallusto, F., A. Lanzavecchia, K. Araki, and R. Ahmed. 2010. From vaccines to memory and back. Immunity 33: 451-463.
24. Doherty, P. C., S. J. Turner, R. G. Webby, and P. G. Thomas. 2006. Influenza and the challenge for immunology. Nat. Immunol. 7: 449-455.
25. Asahi-Ozaki, Y., S. Itamura, T. Ichinohe, P. Strong, S. Tamura, H. Takahashi, H. Sawa, M. Moriyama, M. Tashiro, T. Sata, et al. 2006. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect. 8: 2706-2714.
26. Jelinek, I., J. N. Leonard, G. E. Price, K. N. Brown, A. Meyer-Manlapat, P. K. Goldsmith, Y. Wang, D. Venzon, S. L. Epstein, and D. M. Segal. 2011. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 186: 2422-2429.
27. Nakaya, H. I., J. Wrammert, E. K. Lee, L. Racioppi, S. Marie-Kunze, W. N. Haining, A. R. Means, S. P. Kasturi, N. Khan, G.-M. Li, et al. 2011. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12: 786-795.
28. Kopecky-Bromberg, S. A., K. A. Fraser, N. Pica, E. Carnero, T. M. Moran, R. W. Franck, M. Tsuji, and P. Palese. 2009. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27: 3766-3774.
29. Wang, X., W. Zhang, F. Liu, M. Zheng, D. Zheng, T. Zhang, Y. Yi, Y. Ding, J. Luo, C. Dai, et al. 2012. Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge. Arch. Virol. 157: 1451-1461.
30. Zinkernagel, R. M., and P. C. Doherty. 1997. The discovery of MHC restriction. Immunol. Today 18: 14-17.
31. Henrickson, S. E., M. Perro, S. M. Loughhead, B. Senman, S. Stutte, M. Quigley, G. Alexe, M. Iannacone, M. P. Flynn, S. Omid, et al. 2013. Antigen availability determines CD8+ T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity 39: 496-507.
32. Stephenson, I., R. Bugarini, K. G. Nicholson, A. Podda, J. M. Wood, M. C. Zambon, and J. M. Katz. 2005. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191: 1210-1215.
33. Teijaro, J. R., C. Ng, A. M. Lee, B. M. Sullivan, K. C. Sheehan, M. Welch, R. D. Schreiber, J. C. de la Torre, and M. B. A. Oldstone. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340: 207-211.
34. Wilson, E. B., D. H. Yamada, H. Elsaesser, J. Herskovitz, J. Deng, G. Cheng, B. J. Aronow, C. L. Karp, and D. G. Brooks. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340: 202-207.
35. Mina, M. J., and K. P. Klugman. 2013. Pathogen replication, host inflammation, and disease in the upper respiratory tract. Infect. Immun. 81: 625-628.
36. Mueller, S. N., W. A. Langley, E. Carnero, A. García-Sastre, and R. Ahmed. 2010. Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. J. Virol. 84: 1847-1855.
37. Turner, S. J., G. Diaz, R. Cross, and P. C. Doherty. 2003. Analysis of clonotype distribution and persistence for an influenza virus-specific CD8+ T cell response. Immunity 18: 549-559.
38. Huber, J. P., and J. D. Farrar. 2011. Regulation of effector and memory T-cell functions by type I interferon. Immunology 132: 466-474.
39. Kohlmeier, J. E., W. W. Reiley, G. Perona-Wright, M. L. Freeman, E. J. Yager, L. M. Connor, E. L. Brincks, T. Cookenham, A. D. Roberts, C. E. Burkum, et al. 2011. Inflammatory chemokine receptors regulate CD8(+) T cell contraction and memory generation following infection. J. Exp. Med. 208: 1621-1634.
40. Epstein, S. L., C.-Y. Lo, J. A. Misplon, and J. R. Bennink. 1998. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J. Immunol. 160: 322-327.
41. Schulz, O., S. S. Diebold, M. Chen, T. I. Näslund, M. A. Nolte, L. Alexopoulou, Y.-T. Azuma, R. A. Flavell, P. Liljeström, and C. Reis e Sousa. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
42. Hervas-Stubbs, S., A. Olivier, F. Boisgerault, N. Thieblemont, and C. Leclerc. 2007. TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood 109: 5318-5326.
43. Ramos, H. J., A. M. Davis, A. G. Cole, J. D. Schatzle, J. Forman, and J. D. Farrar. 2009. Reciprocal responsiveness to interleukin-12 and interferonalpha specifies human CD8+ effector versus central memory T-cell fates. Blood 113: 5516-5525.
44. Wang, Y., M. Cella, S. Gilfillan, and M. Colonna. 2010. Cutting edge: polyinosinic: polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J. Immunol. 184: 2751-2755.
45. Schneider-Ohrum, K., B. M. Giles, H. K. Weirback, B. L. Williams, D. R. DeAlmeida, and T. M. Ross. 2011. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine 29: 9081-9092.